For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 11,708,906 | |||
| General and administrative | 8,491,125 | |||
| Total operating expenses | 20,200,031 | |||
| Loss from operations | -20,200,031 | |||
| Gain on remeasurement of warrant liabilities | 89,010 | |||
| Interest expense | 13,402 | |||
| Interest income | 311,370 | |||
| Other expense, net | -32,960 | |||
| Total other income, net | 354,018 | |||
| Loss before provision for income taxes | -19,846,013 | |||
| Provision for income taxes | 18,889 | |||
| Net loss | -19,864,902 | |||
| Basic EPS | -5.48 | |||
| Basic Average Shares | 3,627,890 | |||
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)